

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

**VOLUNTARY ANNOUNCEMENT
CLINICAL RESEARCH RESULTS OF
EVALUATION OF THE SAFETY AND IMMUNOGENICITY OF TWO
TYPES OF RECOMBINANT COVID-19 VACCINES (ADENOVIRUS
TYPE 5 VECTOR) IN A POPULATION AGED 6 TO 17 YEARS**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that, the Company has initiated a clinical study on the Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for inhalation (trade name: Convidecia Air™) to evaluate of the safety and immunogenicity of two types of Recombinant COVID-19 Vaccines (Adenovirus Type 5 Vector), consisting of Convidecia Air™ and Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia®), in a population aged 6 to 17 years, and has received preliminary data.

Clinical Studies and Principal Results

The clinical study was initiated in April 2022 in Beijing and Hunan, with a total of 360 participants aged 6-17 years enrolled, and long-term follow-up is ongoing. The study consists of a primary immunization group and a booster immunization group. Participants who had not received any COVID-19 vaccines were enrolled in the primary immunization group to receive two doses of Convidecia Air™. Participants who had received two doses of inactivated vaccine at least 3 months prior were enrolled in the booster immunization group to receive either Convidecia Air™ (the “**Inhalation Group**”), Convidecia® (the “**Intramuscular Group**”) or COVID-19 inactivated vaccine (the “**Inactivated Group**”) in a 3:1:1 ratio. Safety cohort, cellular immunity cohort and immuno-persistency cohort were set up to evaluate laboratory safety indicators, cellular immunity and duration of immunity, respectively.

1. Safety

The overall incidence of adverse reactions in the Inhalation Group was 15.91% within 28 days post vaccination, which was lower than that of the control groups. Adverse reactions in the Inhalation Group were mainly mild (Grade 1), and the incidence of Grade 3 was only 0.45%. No special safety risks were identified during the study period.

2. Immunogenicity

ELISA S-RBD IgG antibody levels before vaccination were similar among three groups and were close to the lower limit of detection. On Day 28 post-vaccination, the GMT of the Inhalation Group reached 4,967 BAU/ml, which was higher than 3,528 BAU/ml in the Intramuscular Group and about 12 times as high as 411 BAU/ml in the Inactivated Group.

The antibody level of the Inhalation Group remained high at 3,380 BAU/ml after 3 months of vaccination, and was 12.4 times as high as that of the Inactivated Group. It is also significantly higher than the WHO standard reference (1,000 BAU/ml).

The level of neutralizing antibodies against SARS-CoV-2 live virus (original strain) was close to negative before vaccination in these groups. On Day 28 post-vaccination, the antibody level of the Inhalation Group reached 462, which was higher than 350 in the Intramuscular Group and significantly higher than 47 in the Inactivated Group. The antibody level of the Inhalation Group was about 10 times as high as that of the Inactivated Group.

Cross-neutralization of Omicron BA.5 pseudovirus using serum sample on Day 28 post-vaccination showed that the GMT of neutralizing antibodies reached 409 in the Inhalation Group, which was higher than 261 in the Intramuscular Group and significantly higher than 46 in the Inactivated Group, and the Inhalation Group was about 9 times as high as that of Inactivated Group.

Considering several unpredictable factors in the process of clinical trials of drugs and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, December 28, 2022

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.